- Home
- ACRV vs OPP Comparison
ACRV vs OPP Comparison
Compare ACRV & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- OPP
- Stock Information
- Founded
- ACRV 2018
- OPP 2010
- Country
- ACRV United States
- OPP United States
- Employees
- ACRV N/A
- OPP N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- OPP Finance/Investors Services
- Sector
- ACRV Health Care
- OPP Finance
- Exchange
- ACRV Nasdaq
- OPP Nasdaq
- Market Cap
- ACRV 170.3M
- OPP 200.8M
- IPO Year
- ACRV 2022
- OPP N/A
- Fundamental
- Price
- ACRV $5.65
- OPP $8.40
- Analyst Decision
- ACRV Strong Buy
- OPP
- Analyst Count
- ACRV 5
- OPP 0
- Target Price
- ACRV $22.40
- OPP N/A
- AVG Volume (30 Days)
- ACRV 50.9K
- OPP 108.0K
- Earning Date
- ACRV 11-13-2024
- OPP 01-01-0001
- Dividend Yield
- ACRV N/A
- OPP 14.41%
- EPS Growth
- ACRV N/A
- OPP N/A
- EPS
- ACRV N/A
- OPP N/A
- Revenue
- ACRV N/A
- OPP N/A
- Revenue This Year
- ACRV N/A
- OPP N/A
- Revenue Next Year
- ACRV N/A
- OPP N/A
- P/E Ratio
- ACRV N/A
- OPP N/A
- Revenue Growth
- ACRV N/A
- OPP N/A
- 52 Week Low
- ACRV $3.19
- OPP $7.26
- 52 Week High
- ACRV $11.90
- OPP $8.83
- Technical
- Relative Strength Index (RSI)
- ACRV 41.71
- OPP 49.56
- Support Level
- ACRV $5.36
- OPP $8.29
- Resistance Level
- ACRV $6.00
- OPP $8.60
- Average True Range (ATR)
- ACRV 0.52
- OPP 0.12
- MACD
- ACRV -0.01
- OPP 0.00
- Stochastic Oscillator
- ACRV 17.74
- OPP 42.86
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.